New guidelines for handling hazardous drugs have been announced by the United States Pharmacopeia (USP). The organization first released USP General Chapter <800>, titled “Hazardous Drugs – Handling in Health Care Settings,” in 2016, and it plans to make the guidance official in December 2019.
This article, published in Pharmacy and Therapeutics, provides background on these standards and gives advice for health care organizations to prepare themselves for compliance. While spironolactone tablets are considered hazardous, CaroSpir does not appear on the NIOSH list of hazardous drugs and does not have a black box warning. The requirements for handling hazardous drugs like spironolactone tablets do not apply to CaroSpir.
The full journal article is available here.
CaroSpir is the first and only FDA-approved oral suspension of the potassium-sparing diuretic spironolactone. Visit www.CaroSpir.com to learn more.